# **URSODIOL ROUNDTABLE**



## **2002 PBCers Meeting**

- Thomas Draime
  - Background –
  - URSO 250/Forte Product Manager/Liver franchise
    - New indications/formulations and authorized generic initiation
  - Healthcare consulting/Market Research/ PR/Advertising
  - HCP/Patient marketing/advocacy
  - Liver PBC/PSC/HCV/HCC
  - Other CV/Hemophilia/ HSCT/NSCLC/ mCRPC/mBC/Obesity/Immuno-oncology
  - Promoting patient-physician communication, information and advocacy



#### Objective of the Ursodiol Roundtable


- Review some of the top questions and comments within the PBCers forums
  - This discussion is to inform people with PBC about some of the details on ursodiol to assist your conversation with your doctor
  - Always consult with YOUR physician on any questions about YOUR treatment plan
    - Everyone is unique in her/his response to medications
- DO NOT make any changes to your treatments WITHOUT consulting your doctor



# Empower yourself with knowledge and connections to live with PBC

#### **Areas of Facebook Questions**

What questions do you have about ursodiol?



#### What is Ursodiol?

- First Line: Ursodeoxycholic Acid/Ursodiol (UDCA)
- This medicine, also known as ursodiol (Actigall, Urso), is commonly used first. It helps move bile through your liver. UDCA doesn't cure primary biliary cholangitis, but it seems to improve liver function and reduce liver scarring.
- Everyone is different in their response to ursodio:
  - Responders
  - Non-responders
  - Intolerant

## **Differences Tablets vs Capsules**

#### **Actigall/Generic Capsules**

- Indication Dissolution of radiolucent, noncalcified gallstones <20 mm in diameter in patients who refuse cholecystectomy or are at increased risk during surgery. Prevention of gallstone formation in obese patients experiencing rapid weight loss.
- Dosage Gallstone Dissolution: 8– 10mg/kg per day in 2–3 divided doses. Prevention: 300mg twice daily
- ▶ Generics launched ~2000
- Insurance coverage based on ingredient vs indication (epocrates)

#### URSO250/Forte/Tablets 250/500 mg

and Generic Tablets

- ► Indication URSO 250 and URSO Forte (ursodiol) tablets are bile acids indicated for the treatment of patients with primary biliary cirrhosis
- Dosage 13-15 mg/kg/day administered in two to four divided doses with food (trials 4 →2)
- Generics launched ~2011
  - Different fillers to save on costs
- Bioequivalency
  - Measure of drug
- Insurance Coverage based on best price/rebate negotiations
- Each manufacturer and tablet/capsule is different different bioequivalency, different fillers, different cost

## Orange Book Approved Ursodiol Tablets/Capsules


- Full list of generic listed products and manufacturers
- RLD original Branded Products

Mkt. Status	Active Ingredient	Proprietary Name	Appl No	Dosage Form	A Route	Strength	→ TE Code	A RLD	⇔ RS	Applicant Holder
RX	URSODIOL	ACTIGALL	N019594	CAPSULE	ORAL	300MG	AB	RLD	RS	ALLERGAN SALES LLC
RX	URSODIOL	URSODIOL	A075517	CAPSULE	ORAL	300MG	AB			EPIC PHARMA LLC
RX	URSODIOL	URSODIOL	A079082	CAPSULE	ORAL	300MG	AB			LANNETT HOLDINGS INC
RX	URSODIOL	URSODIOL	A090530	CAPSULE	ORAL	300MG	AB			MYLAN PHARMACEUTICALS INC
RX	URSODIOL	URSODIOL	A075592	CAPSULE	ORAL	300MG	AB			TEVA PHARMACEUTICALS USA
RX	URSODIOL	URSO 250	N020675	TABLET	ORAL	250MG	AB	RLD		FOREST LABORATORIES INC
RX	URSODIOL	URSO FORTE	N020675	TABLET	ORAL	500MG	AB	RLD	RS	FOREST LABORATORIES INC
RX	URSODIOL	URSODIOL	A090801	TABLET	ORAL	250MG	AB		_	GLENMARK GENERICS LTD
RX	URSODIOL	URSODIOL	A200826	TABLET	ORAL	250MG	AB			IMPAX LABORATORIES INC
RX	URSODIOL	URSODIOL	A202540	TABLET	ORAL	250MG	AB			PAR PHARMACEUTICAL INC
RX	URSODIOL	URSODIOL	A090801	TABLET	ORAL	500MG	AB			GLENMARK GENERICS LTD
RX	URSODIOL	URSODIOL	A200826	TABLET	ORAL	500MG	AB			IMPAX LABORATORIES INC
RX	URSODIOL	URSODIOL	A202540	TABLET	ORAL	500MG	AB			PAR PHARMACEUTICAL INC
DISCN	URSODIOL	ACTIGALL	N019594	CAPSULE	ORAL	150MG				ALLERGAN SALES LLC
DISCN	URSODIOL	URSODIOL	A077895	CAPSULE	ORAL	300MG				IMPAX LABORATORIES INC
DISCN	URSODIOL	URSODIOL	A079184	TABLET	ORAL	250MG				TEVA PHARMACEUTICALS USA INC
DISCN	URSODIOL	URSODIOL	A079184	TABLET	ORAL	500MG				TEVA PHARMACEUTICALS USA INC
Mkt. Status	Active Ingredient	Proprietary Name	Appl No	Dosage Form	Route	Strength	TE Code	RLD	RS	Applicant Holder

#### Which Formulation of Ursodiol are You On?

65% of survey respondants are on Tablet formulation

Of those, 57% are on a generic



**Tablet Breakout** 

## **Ursodiol Dosage and Efficacy**

# Optimal dosage for PBC is 13-15 mg/kg twice a day

Recommended adult dosage: 13-15 mg/kg/day administered in two to four divided doses with food (2.1) Scored URSO Forte tablet: scored tablet can be broken in halves to provide recommended dosage


Clinical trials/approval is based on weight

Efficacy above or below 13-15 mg/kg in clinical study dose ranging deemed not optimal

Time of day: 2 to 4 times a day recommended Actual PBCers time of day: 59% 2x a day


Efficacy based on stage: Range of stages studied (I-IV)

Food effect: Recommended to be taken with food



NOTE – Actigall Dosing for Gallstone Dissolution: 8– 10mg/kg per day in 2–3 divided doses. Prevention: 300mg twice daily. (NOT PBC)


## Am I on the Right Dose of Ursodiol?



74% have the perception they are on the right average dose (13-15mg.kg) of ursodiol based on weight

75% are approximately on the recommended dose (13-15mg.kg) of ursodiol based on weight





## Clinical and Post Marketing Side Effects / AE of Ursodiol

## Original Reported Adverse Events from Clinical trials

The following table summarizes the adverse reactions observed in two placebo-controlled clinical trials.

ADVERSE REACTIONS	VISIT AT 12 MONTHS		VISIT AT 24 MONTHS		
	UDCA n (%)	Placebo n (%)	UDCA n (%)	Placebo n (%)	
Diarrhea			1 (1.32)		
Elevated creatinine			1 (1.32)		
Elevated blood glucose	1 (1.18)		1 (1.32)		
Leukopenia			2 (2.63)		
Peptic ulcer			1 (1.32)		
Skin rash			2 (2.63)		
Thrombocytopenia			1 (1.32)		


Note: Those adverse reactions occurring at the same or higher incidence in the placebo as in the UDCA group have been deleted from this table (this includes diarrhea and thrombocytopenia at 12 months, nausea/vomiting, fever and other toxicity).

UDCA = Ursodeoxycholic acid = Ursodiol

#### **Post Launch REPORTED Side Effects (ALL)**

- Gastrointestinal disorders: abdominal discomfort, abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting.
- General disorders and administration site conditions: malaise, peripheral edema, pyrexia.
- Hepatobiliary disorders: jaundice (or aggravation of preexisting jaundice).
- Immune System Disorders: Drug hypersensitivity to include facial edema, urticaria, angioedema and laryngeal edema.
- Abnormal Laboratory Tests: ALT increased, AST increased, blood alkaline phosphatase increased, blood bilirubin increased, γ-GT increased, hepatic enzyme increased, liver function test abnormal, transaminases increased.
- Musculoskeletal and connective tissue disorders: myalgia
- Nervous system disorders: dizziness, headache.
- Respiratory, thoracic and mediastinal disorders: cough.
- Skin and subcutaneous tissue disorder: alopecia, pruritus, rash

## Side Effects / AE of Ursodiol Observed in Survey



38 people (out of 242, ~16%) in the PBCers
Survey stopped ursodiol due to side effects

ALWAYS report any Side Effects with your Doctor! These need to be reported back to the pharmaceutical company.

\*Other side effects 5% or below: Headache, Itching (from med), Weight loss, Urinary tract infection, Other

## **Long-Term use of Ursodiol**

#### Results of long-term ursodiol treatment for patients with primary biliary cirrhosis

Roberta Jorgensen MS, RN, Paul Angulo MD, E Rolland Dickson MD & Keith D Lindor MD 🗷

American Journal of Gastroenterology **97**, 2647–2650 (2002) doi:10.1111/j.1572-0241.2002.06043.x Download Citation Received: 28 October 2001 Accepted: 19 April 2002 Published: 01 October 2002

#### CONCLUSIONS:

UDCA appears to be of most benefit when instituted in early stage disease. Although a substantial percentage of patients will achieve biochemical normalization on UDCA alone, there is a continued need for therapeutic options for others who have less complete biochemical responses.

#### AASLD PRACTICE GUIDELINES

#### **Primary Biliary Cirrhosis**

Keith D. Lindor, <sup>1</sup> M. Eric Gershwin, <sup>2</sup> Raoul Poupon, <sup>3</sup> Marshall Kaplan, <sup>4</sup> Nora V. Bergasa, <sup>5</sup> and E. Jenny Heathcote UDCA is widely used and has demonstrated the ability to produce a reduction in need for liver transplantation for this condition. <sup>123</sup> The drug is used for patients with any stage of PBC as long as their liver biochemistries are abnormal. A liver biopsy in not required for the diagnosis for PBC in many settings, and the stage of biopsy does not determine whether UDCA should be used but may have an impact on developing treatment strategies. <sup>111</sup> Patients with earlier histologic stage in general respond more favorably to UDCA, but even patients with advanced stage disease may derive improvement in survival or avoidance of need for liver transplantation with this therapy. <sup>42</sup>

Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. HEPATOLOGY 1999;29:644-647.

## **Comparison of Tablet Inactive Ingredients**

Glenmark Generic	Par Pharmaceuticals	URSO 250	Impax Labs
Inactive Ingredients	INACTIVE INGREDIENTS	Inactive Ingredients	nactive Ingredients
Ingredient Name	Ingredient Name	Ingredient Name	Ingredient Name
CELLULOSE, MICROCRYSTALLINE	MEDIUM-CHAIN TRIGLYCERIDES (UNII: C9H2L21V7U)	microcrystalline cellulose	CELLULOSE, MICROCRYSTALLINE
POVIDONES	COPOVIDONE (UNII: D9C330MD8B)	povidone	SILICON DIOXIDE
SODIUM STARCH GLYCOLATE TYPE A POTATO	HYPROMELLOSES (UNII: 3NXW29V3WO)	sodium starch glycolate	POVIDONE
MAGNESIUM STEARATE	CELLULOSE, MICROCRYSTALLINE (U NII: OP1R32D61U)	magnesium stearate	MAGNESIUM STEARATE
ETHYLCELLULOSES	MAGNESIUM STEARATE (UNII: 70097M6I30)	ethylcellulose	LACTOSE MONOHYDRATE
DIBUTYL SEBACATE	POLYDEXTROSE (UNII: VH2XOU12IE)	dibutyl sebacate	HYPROMELLOSES
CARNAUBA WAX	POLYETHYLENE GLYCOL 3350 (UNII: G2M7P15E5P)	carnauba wax	TITANIUM DIOXIDE
HYPROMELLOSES	SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	hydroxypropyl methylcellulose	SODIUM STARCH GLYCOLATE TYPE A POTATO
POLYETHYLENE GLYCOL 3350	TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	PEG 3350	POLYETHYLENE GLYCOL 400
POLYETHYLENE GLYCOL 8000	POVIDONE (UNII: FZ989GH94E)	PEG 8000	
CETYL ALCOHOL		cetyl alcohol	
SODIUM LAURYL SULFATE		sodium lauryl sulfate	
		hydrogen peroxide	

Similar yet ... different

Be aware of ingredients and how they affect YOU

Medium chain triglycerides are for dietary use in people whose bodies cannot digest certain foods properly. This includes people who are gluten or lactose intolerant, or who have unintended weight loss or need increased calories for other medical reasons.





URSO 250	Epic Pharma	Allergan	<b>Lannett Company</b>
Inactive Ingredients	INACTIVE INGREDIENTS	INACTIVE INGREDIENTS	INACTIVE INGREDIENT
Ingredient Name	Ingredient Name	Ingredient Name	Ingredient Name
microcrystalline cellulose	STARCH, CORN (UNII: 08232NY3SJ)	Colloidal silicon dioxide	STARCH, CORN (UNII: 08232NY3SJ)
povidone	MAGNESIUM STEARATE (UNII: 70097M6I30)	Magnesium stearate	SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
sodium starch glycolate	SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	starch (corn)	MAGNESIUM STEARATE (UNII: 70097M6I30)
magnesium stearate	D&C RED NO. 28 (UNII: 767IP0Y5NH)	ferric oxide	FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
ethylcellulose	D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)	gelatin	FD&C RED NO. 40 (UNII: WZB9127XOA)
dibutyl sebacate	FD&C BLUE NO. 1 (UNII: H3R47K3TBD)	titanium dioxide	FD&C YELLOW NO. 6 (UN H77VEI93A8)
carnauba wax	FD&C BLUE NO. 2 (UNII: L06K8R7DQK)	black iron oxide	GELATIN (UNII: 2G86QN327L)
hydroxypropyl methylcellulose	FD&C RED NO. 40 (UNII: WZB9127XOA)		TITANIUM DIOXIDE (UNII 15FIX9V2JP)
PEG 3350	GELATIN (UNII: 2G86QN327L)		SHELLAC (UNII: 46N107B71O)
PEG 8000	FERROSOFERRIC OXIDE (UNII: XM0M87F357)		ALCOHOL (UNII: 3K9958V90M)
cetyl alcohol	TITANIUM DIOXIDE (UNII: 15FIX9V2JP)		FERROSOFERRIC OXIDE (UNII: XM0M87F35
sodium lauryl sulfate	SHELLAC (UNII: 46N107B71O)		BUTYL ALCOHOL (UNII: 8PJ61P6TS3)
hydrogen peroxide	PROPYLENE GLYCOL (UNII: 6DC9Q167V3)		PROPYLENE GLYCOL (UI 6DC9Q167V3)
			METHYL ALCOHOL (UNII Y4S76JWI15)
		AILYMED -	ALUMINUM OXIDE (UNII: LMI26O6933) FD&C BLUE NO. 2 (UNII:
https://d	dailymed.nlm		L06K8R7DQK) D&C YELLOW NO. 10 (UN 35SW5USQ3G)

# Comparison of Capsule Inactive Ingredients

Actigall launched in 1987

Generics launched in 2000+

Comparison to raise awareness of what is in your tablet/capsule, not to compare efficacy.

**Everyone responds differently!** 





## **Most Common Ursodiol Drug-Drug Interactions (DDI)**

#### Most common side effects from clinical trials included:

#### DRUG INTERACTIONS

7.1 Bile Acid Sequestering Agents

Bile acid sequestering agents such as cholestyramine and colestipol may interfere with the action of URSO 250 and URSO Forte by reducing its absorption.

7.2 Aluminum-based Antacids

Aluminum-based antacids have been shown to adsorb bile acids in vitro and may be expected to interfere with URSO 250 and URSO Forte in the same manner as the bile acid sequestering agents.

7.3 Drugs Affecting Lipid Metabolism

Estrogens, oral contraceptives, and clofibrate (and perhaps other lipid-lowering drugs) increase hepatic cholesterol secretion and encourage cholesterol gallstone formation and hence may counteract the effectiveness of URSO 250 and URSO Forte.

#### Common medications checked in combination with Urso (ursodiol)


Albuterol; Calcium 600 D (calcium / vitamin d); Flonase (fluticasone nasal); gabapentin; lactulose; Lasix (furosemide); levothyroxine; Nexium (esomeprazole); Omeprazole; oxycodone; prednisone; Protonix (pantoprazole); spironolactone; Symbicort (budesonide / formoterol); Synthroid (levothyroxine); trazodone; Vitamin D2 (ergocalciferol); Vitamin D3 (cholecalciferol); Xanax (alprazolam); Zofran (ondansetron)

Health Plan Name	Provider	Plan Type	Coverage				
Actigall 1							
Amerigroup (Texas)	Amerigroup	Managed Medicaid	Tier 1 Non-Preferred PA 93				
BlueCross BlueShield Texas Basic	BlueCross BlueShield Texas	Commercial	Tier 3 Non-Preferred				
CVS Caremark Performance Standard Control	CVS/Caremark	PBM	Tier 3 Non-Preferred				
Humana Walmart Rx PDP	Humana	Medicare PDP	NC Not Covered				
Silverscript Choice	SilverScript	Medicare PDP	NC Not Covered				
Superior Health Plan	Superior HealthPlan	Managed Medicaid	Tier 1 Non-Preferred PA 93				
UnitedHealthcare Advantage 3-Tier	United	Commercial	Tier 3 Non-Preferred				
UnitedHealthcare Community Plan (Texas)	UnitedHealthcare Community Plan (TX)	Managed Medicaid	Tier 1 Non-Preferred PA 93				
URSO Forte 1							
Amerigroup (Texas)	Amerigroup	Managed Medicaid	Tier 1 Non-Preferred PA 93				
BlueCross BlueShield Texas Basic	BlueCross BlueShield Texas	Commercial	Tier 3 Non-Preferred				
CVS Caremark Performance Standard Control	CVS/Caremark	PBM	Tier 3 Non-Preferred				
Humana Walmart Rx PDP	Humana	Medicare PDP	NC Not Covered				
Silverscript Choice	SilverScript	Medicare PDP	NC Not Covered				
Superior Health Plan	Superior HealthPlan	Managed Medicaid	Tier 1 Non-Preferred PA 93				
UnitedHealthcare Advantage 3-Tier	United	Commercial	Tier 3 Non-Preferred				
UnitedHealthcare Community Plan (Texas)	UnitedHealthcare Community Plan (TX)	Managed Medicaid	Tier 1 Non-Preferred PA 93				
Ursodiol 🐧							
Amerigroup (Texas)	Amerigroup	Managed Medicaid	Tier 1 Preferred				
BlueCross BlueShield Texas Basic	BlueCross BlueShield Texas	Commercial	Tier 1 Preferred				
CVS Caremark Performance Standard Control	CVS/Caremark	PBM	Tier 1 Preferred				
Humana Walmart Rx PDP	Humana	Medicare PDP	Tier 3 Preferred 10				
Silverscript Choice	SilverScript	Medicare PDP	Tier 4 Non-Preferred 10				
Superior Health Plan	Superior HealthPlan	Managed Medicaid	Tier 1 Preferred				
UnitedHealthcare Advantage 3-Tier	United	Commercial	Tier 1 Preferred				
UnitedHealthcare Community Plan (Texas)	UnitedHealthcare Community Plan (TX)	Managed Medicaid	Tier 1 Preferred				

#### **COSTS/Product assistance**

- Approximately 25% of respondents have difficulty covering Ursodiol co-pays for periods of time throughout the year
- 65% with difficulty paying for ursodiol co-pay have not reached out through the appeals process

#### **USE OF APPEAL PROCESS\***





## **Closing Thoughts**



Reach out to PBCers members, doctor's office and manufacturers



Learn about your treatments & talk WITH your hep/gastro on plans



Empower yourself with knowledge and connections to live with PBC

## **Other Discussion Points**



#### **Breaker Sections**



Connect with other PBC patients, family and friends.



Learn about PBC: History, current and future treatments & research



Empower yourself with knowledge and connections to live with PBC



